Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multi-Center Open-label Randomized Study of CAPecitabine in Combination With ELAcestrant Versus Capecitabine Alone in Advanced Estrogen Receptor-Positive Breast Cancer (CAPELA)

NCT07222215 is registered in ClinicalTrials.gov with Kristina A. Fanucci as lead sponsor.

NCT NCT07222215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07222215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multi-Center Open-label Randomized Study of CAPecitabine in Combination With ELAcestrant Versus Capecitabine Alone in Advanced Estrogen Receptor-Positive Breast Cancer (CAPELA)
Lead sponsor
Kristina A. Fanucci
Phase
Phase 2
Overall status
Recruiting
Start date
January 16, 2026
Completion date
October 1, 2030
Enrollment
297 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast neoplasms, er wildtype, esr1 gene mutation, estrogen-receptor-positive breast cancer, her2- breast cancer, hormone receptor positive breast cancer, human epidermal growth factor 2 negative carcinoma of breast, metastatic breast cancer